Microbiome

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial […]

Children under age two  who take antibiotics are at greater risk for childhood-onset asthma, respiratory allergies, eczema, coeliac disease, obesity and attention deficit hyperactivity disorder, according to a paper written jointly by Mayo Clinic and Rutgers researchers. In a study published in the journal Mayo Clinic Proceedings, the researchers looked at 14,572 children in Olmsted […]

Charlie Badham, Corporate Development, 4D pharma, spoke to Lu Rahman about the growing significance of microbiomics in the quest for new therapeutics   LR: How important are microbiomics in the development of new therapeutics and how does understanding gut bacteria help us find treatments for new diseases? CB: The microbiome and live biotherapeutic products (LBPs) […]

6 July 2020 Image: Science in HD Eremid Research Services is the new name for the commercial arm of research organisation, DHMRI. Eremid continues to specialise in the provision of genomics, metabolomics, NMR and vivarium research services, offering expertise in areas including human health, food & nutrition, and AgBiotech. The company offers a ‘multi-omics’ approach, working with clients across the globe […]

25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and population health have been asking for a validated, ambient-temperature solution […]

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the […]

By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to improve human health, biotech and […]

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue […]

How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely to focus their efforts, and […]

Microfluidics – Driving Innovation and Streamlining Single Cell Analysis By Dr Frank F. Craig Microfluidics platforms that harness picodroplet technology (picolitre volume aqueous droplets in stabilised oil emulsions) are unlocking the potential of single cell analysis to enable exciting new discoveries and advances with the potential to transform scientific research, drug development and precision medicine. […]